JP Morgan Chase
ACRS icon

JP Morgan Chase’s Aclaris Therapeutics ACRS Stock Holding History

JP Morgan Chase’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.7M Sell
486,633
-139,330
-22% -$470K ﹤0.01% 4233
2025
Q4 		$1.88M Sell
625,963
-132,613
-17% -$335K ﹤0.01% 4118
2025
Q3 		$1.44M Buy
758,576
+134,784
+22% +$235K ﹤0.01% 4322
2025
Q2 		$886K Buy
623,792
+125,071
+25% +$169K ﹤0.01% 4454
2025
Q1 		$763K Buy
498,721
+410,401
+465% +$875K ﹤0.01% 4524
2024
Q4 		$219K Buy
88,320
+79,844
+942% +$199K ﹤0.01% 5434
2024
Q3 		$9.75K Sell
8,476
-428
-5% -$525 ﹤0.01% 6371
2024
Q2 		$9.79K Sell
8,904
-60,764
-87% -$71.4K ﹤0.01% 6269
2024
Q1 		$86.4K Buy
69,668
+95
+0.1% +$113 ﹤0.01% 5739
2023
Q4 		$73.1K Sell
69,573
-330,748
-83% -$1.01M ﹤0.01% 5871
2023
Q3 		$2.74M Sell
400,321
-26,638
-6% -$228K ﹤0.01% 3306
2023
Q2 		$4.43M Sell
426,959
-2,208
-0.5% -$20K ﹤0.01% 2956
2023
Q1 		$3.47M Buy
429,167
+1,507
+0.4% +$19.1K ﹤0.01% 3104
2022
Q4 		$6.74M Sell
427,660
-25,305
-6% -$407K ﹤0.01% 2588
2022
Q3 		$7.13M Sell
452,965
-8,631
-2% -$136K ﹤0.01% 2433
2022
Q2 		$6.44M Buy
461,596
+416,946
+934% +$5.84M ﹤0.01% 2552
2022
Q1 		$770K Buy
44,650
+7,448
+20% +$102K ﹤0.01% 4437
2021
Q4 		$541K Buy
37,202
+7,376
+25% +$112K ﹤0.01% 4780
2021
Q3 		$536K Buy
29,826
+3,049
+11% +$48.9K ﹤0.01% 4674
2021
Q2 		$470K Buy
26,777
+26,756
+127,410% +$608K ﹤0.01% 4734
2021
Q1 		$1K Sell
21
-16
-43% -$313 ﹤0.01% 5961
2020
Q4 		$0 Hold
37
– – ﹤0.01% 5590
2020
Q3 		$0 Hold
37
– – ﹤0.01% 5442
2020
Q2 		$0 Sell
37
-179,044
-100% -$240K ﹤0.01% 5328
2020
Q1 		$186K Sell
179,081
-26,387
-13% -$35.9K ﹤0.01% 4296
2019
Q4 		$388K Sell
205,468
-10,784
-5% -$17.9K ﹤0.01% 4367
2019
Q3 		$233K Sell
216,252
-192,010
-47% -$272K ﹤0.01% 4561
2019
Q2 		$870K Buy
408,262
+162,458
+66% +$885K ﹤0.01% 3946
2019
Q1 		$1.47M Buy
245,804
+51,660
+27% +$342K ﹤0.01% 3546
2018
Q4 		$1.44M Buy
194,144
+5,764
+3% +$59.4K ﹤0.01% 3516
2018
Q3 		$2.73M Buy
188,380
+4,351
+2% +$74.6K ﹤0.01% 3236
2018
Q2 		$3.67M Sell
184,029
-6,252
-3% -$116K ﹤0.01% 2933
2018
Q1 		$3.33M Buy
190,281
+185,266
+3,694% +$3.93M ﹤0.01% 2908
2017
Q4 		$124K Buy
+5,015
New +$122K ﹤0.01% 4584
2017
Q1 		– Sell
-7,620
Closed -$207K – 5019
2016
Q4 		$207K Buy
+7,620
New +$194K ﹤0.01% 4170

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

JP Morgan Chase's ACRS Position: Q1 2026 in Review

JP Morgan Chase reduced its Aclaris Therapeutics (ACRS) stake by 22% in Q1 2026, selling an estimated $470K and leaving 486,633 shares worth $1.7M. The position accounts for ﹤0.01% of the portfolio, ranked #4233.

JP Morgan Chase first reported a position in ACRS in Q4 2016 and has held it in 35 quarters since. The position peaked at $7.13M in Q3 2022. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • JP Morgan Chase held 486,633 shares of Aclaris Therapeutics worth $1.7M as of Q1 2026.
  • JP Morgan Chase sold 139,330 Aclaris Therapeutics shares in Q1 2026, an estimated $470K.
  • Aclaris Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4233 holding.
  • JP Morgan Chase first reported a position in Aclaris Therapeutics in Q4 2016 and has held it in 35 quarters since.
  • JP Morgan Chase's Aclaris Therapeutics position peaked at $7.13M in Q3 2022.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.